Cover Image
市場調查報告書

人體用醫藥品的動物使用:交叉醫藥品的目前趨勢、未來的商業性展望

Human Drugs For Veterinary Use - Current Trends and Future Commercial Prospects for Crossover Drugs

出版商 CBR Pharma Insights 商品編碼 359272
出版日期 內容資訊 英文 60 Pages
訂單完成後即時交付
價格
Back to Top
人體用醫藥品的動物使用:交叉醫藥品的目前趨勢、未來的商業性展望 Human Drugs For Veterinary Use - Current Trends and Future Commercial Prospects for Crossover Drugs
出版日期: 2016年05月01日 內容資訊: 英文 60 Pages
簡介

本報告提供動物醫療產業專家進行的醫藥品的標籤指示外用藥 (ELDU) 、對動物的應用以及其他的指南、規定等相關調查,人體用醫藥品對動物使用與疾病概要,競爭的治療藥,製造商資訊,投藥形態,治療成本以及其他的行銷資訊考察,交叉醫藥品市場推動因素、抑制因素分析等彙整資料。

簡介

對人體用醫藥品的動物醫療用途的法規

  • 美國對人體用醫藥品的動物醫療用途的法規
  • 標籤指示外用藥 (ELDU) 的演算法
  • 加拿大對人體用醫藥品的動物醫療用途的法規
  • EU對人體用醫藥品的動物醫療用途的法規

促進動物領域的人體用醫藥品需求的未滿足需求、要素

動物醫療的人體用醫藥品的適應:案例研究

  • 對狗的Lysodren (Mitotane)使用
  • 對狗、貓的Fluoxetine hydrochloride (Prozac) 使用
  • 對狗、貓的Benazepril (Lotensin, Fortekor) 使用
  • 對馬、狗的Quinidine Sulfate 使用
  • 狗、貓的化療

人體用醫藥品的動物使用:主要的上市藥

  • Sildenafil
  • Methimazole
  • Amlodipine
  • Phenobarbital
  • Levothyroxine
  • Acetaminophen
  • Hydroxyzine
  • Humulin N
  • Pentoxifylline
  • Bethanechol
  • 狗、貓所採用的人體用醫藥品、成藥

交叉醫藥品市場促進要素

交叉醫藥品市場抑制因素

交叉醫藥品市場上全球性第一流企業

  • Zoetis
  • Boehringer Ingelheim Vetmedica
  • Merck/MSD Animal Health
  • Elanco (Eli Lilly)
  • Merial (Sanofi)
  • Bayer Animal Health

交叉醫藥品市場上新興企業

對動物用醫藥品企業來說符合成本效益的經營模式

經營模式、交叉醫藥品:實例、未來的重點領域

動物醫療企業採用的使用交叉醫藥品的商務策略

動物醫療市場上的未來展望

參考資料

目錄
Product Code: GBI069CBR

Summary

GBI Research's latest report, "Human Drugs For Veterinary Use - Current Trends and Future Commercial Prospects for Crossover Drugs", discusses global commercial trends and prospects for human medicines applied in the veterinary setting, also called crossover drugs. A wide range of human drugs continue to be applied in the veterinary space due to a lack of approved animal therapies, convenience and the rising costs of veterinary research.

This new report provides insights into Extra-label Drug Use (ELDU), its application in the veterinary setting and other guidelines and regulations followed by professionals in the animal health industry. Through a series of in-depth case studies this report provides insights into the rationale for the transition of several human drugs to the veterinary setting as well as disease overviews, competing treatments, manufacturer information, dosage forms, cost of therapy and other insightful marketing information. Our new study also identifies and explores important drivers and restraints of the crossover drugs market.

Information leveraged from our robust industry-leading database shows a diverse range of marketed human drugs being used in companion animals especially cats, dogs and horses. Our new report includes detailed profiles of key animal health companies with diverse portfolios of crossover drugs as well as strategies being employed by competitors in this market to leverage human therapies into the veterinary space. Additionally, we identify emerging companies marketing various crossover drugs across a range of therapy areas.

GBI Research conducted extensive research in order to provide a comprehensive view of the current trends and commercial prospects for crossover drugs. This new report adds to our unique portfolio of trusted industry analyses that enable our clients to assess the most promising commercial areas in the market and exploit key business opportunities.

Scope

  • What regulations need to be followed when prescribing human drugs off-label to pets and food-producing animals?
  • What are the main factors driving the prescription of human medicines in animals?
  • Marketed human drugs commonly used in companion animals
  • What are the differences in indication between the human and veterinary setting?
  • What are the dosage and side effects of those specific drugs in animals?
  • Are there any existing and approved veterinary therapies for the same indication? Why is the human drug preferred over the approved animal drug?
  • What are the key drivers and barriers that affect ELDU of human drugs in animals?
  • What is currently restricting the crossover drugs market?
  • What are the key animal health companies with prominent crossover drug portfolios?
  • Explore recent financial performance, crossover drugs brands, and the number of species supported through their animal health product portfolio
  • Identify emerging companies in the animal health market investigating and marketing crossover drugs

Key Reasons to Purchase

This report will allow you to -

  • Gain insightful analyses and understanding of the crossover drugs market: This report describes and assesses the key differences between the human and animal healthcare markets, areas of unmet need in the veterinary market and key factors responsible for ELDU in the veterinary setting.
  • Assess high-profile marketed human products used for treating animals: Our new study provides analyses of the key human therapies that have the potential to be transitioned in the veterinary space.
  • Identify the most important drivers and restraints of the crossover drugs market: This report provides insights regarding what is currently driving the prescription and application of human drugs in the veterinary setting as well as the current factors restraining further transition.
  • Review the key and emerging companies that market crossover drugs and the business strategies being employed: This report assesses current tactics used by top veterinary pharmaceutical companies in manufacturing and marketing cross-over drugs. It also reviews the emerging companies that manufacture cross-over drugs for various indications.
  • Assess future trends in the veterinary market: This report contains our prediction for what the future holds for crossover drugs, future treatment landscapes and evolving marketing models.

Table of Contents

Introduction

  • The Human and Animal Healthcare Industries
  • Human Drugs for Veterinary Use: Overview

Regulations for Human Drugs Applied in Veterinary Medicine

  • Regulation of Human Drugs for Veterinary Use in the US
  • Extra-Label Drug Use Algorithm
  • Regulation of Human Drugs for Veterinary Use in Canada
  • Regulation of Human Drugs for Veterinary Use in the EU

Unmet Needs and Factors Promoting Demand for Human Drugs in the Veterinary Space

Human Drugs Applied in Veterinary Medicine: Case Studies

  • Lysodren (Mitotane) in Dogs
  • Fluoxetine hydrochloride (Prozac) in Dogs and Cats
  • Benazepril (Lotensin, Fortekor) in Dogs and Cats
  • Quinidine Sulfate in Horses and Dogs
  • Chemotherapy in Dogs and Cats

Human Drugs for Veterinary Use: Key Marketed Products

  • Sildenafil
  • Methimazole
  • Amlodipine
  • Phenobarbital
  • Levothyroxine
  • Acetaminophen
  • Hydroxyzine
  • Humulin N
  • Pentoxifylline
  • Bethanechol
  • Human Prescription and OTC Drugs used in Dogs and Cats

Factors Driving the Crossover Drugs Market

Factors Restraining the Crossover Drugs Market

Key Established Global Players in the Crossover Drugs Market

  • Zoetis
  • Boehringer Ingelheim Vetmedica
  • Merck/MSD Animal Health
  • Elanco (Eli Lilly)
  • Merial (Sanofi)
  • Bayer Animal Health

Emerging Players in the Crossover Drugs Market

Cost-Efficient Business Model for Veterinary Pharmaceutical Companies

Business Models and Crossover Drugs: Examples and Future Focus Areas

Business Strategies Employed by Animal Health Companies with Crossover Drugs

Future Outlook in the Animal Health Market

Bibliography

Back to Top